Not All TF Activity Assays Measure Tissue Factor – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Ana T.A. Sachetto et al, adding:
“Measuring tissue factor activity in plasma sounds straightforward.
In reality, it’s anything but!
TF-positive extracellular vesicles are increasingly linked to thrombosis, cancer, sepsis, and inflammatory disease, but accurately detecting low circulating TF activity remains a major technical challenge.
A new RPTH methodological study systematically evaluated 3 commercial plasma TF activity assays against the well-established Chapel Hill EV TF activity assay.
What did they find?
All 3 kits detected recombinant TF (Innovin)
- But sensitivity and specificity varied substantially
- Plasma background absorbance and hemolysis interfered with measurements
- Some assays detected large amounts of TF-independent activity
- Plasma clotting occurred in certain assay systems
The strongest performer?
The Chapel Hill EV TF activity assay remained the most sensitive and specific approach for detecting TF-dependent activity.
Compared with commercial assays, fold increase in LPS-stimulated samples vs controls:
- Chapel Hill assay: 33-fold
- Abcam: 11-fold
- AssaySense: 5-fold
One important message from this paper:
Not all ‘TF activity’ measurements actually reflect tissue factor. Without proper controls, plasma background, EV-independent coagulation activity, and optical interference can all distort interpretation.
A valuable technical contribution for anyone studying extracellular vesicles, coagulation, immunothrombosis, or plasma biomarkers.”
Title: Evaluation of 3 commercial assays for the measurement of tissue factor activity in human plasma
Authors: Ana T.A. Sachetto, Dougald M. Monroe, Nigel Mackman

Other articles about RPTH Journal on Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering